Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 38 articles:
HTML format
Text format



Single Articles


    April 2017
  1. LUO C, Shen J
    Research progress in advanced melanoma.
    Cancer Lett. 2017 Apr 3. pii: S0304-3835(17)30219.
    PubMed     Text format     Abstract available


    February 2017
  2. XU DH, Zhu Z, Xiao H, Wakefield MR, et al
    Unveil the mysterious mask of cytokine-based immunotherapy for melanoma.
    Cancer Lett. 2017 Feb 28. pii: S0304-3835(17)30131.
    PubMed     Text format     Abstract available


  3. GUTTERIDGE RE, Singh CK, Ndiaye MA, Ahmad N, et al
    Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma.
    Cancer Lett. 2017 Feb 22. pii: S0304-3835(17)30121.
    PubMed     Text format     Abstract available


  4. DE SOUZA LM, Robertson BM, Robertson GP
    Future of Circulating Tumor Cells in the Melanoma Clinical and Research Laboratory Settings.
    Cancer Lett. 2017 Feb 2. pii: S0304-3835(17)30064.
    PubMed     Text format     Abstract available


    January 2017
  5. PEARLMAN RL, Montes de Oca MK, Pal HC, Afaq F, et al
    Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.
    Cancer Lett. 2017 Jan 25. pii: S0304-3835(17)30070.
    PubMed     Text format     Abstract available


    October 2016
  6. CHOLEWA BD, Ndiaye MA, Huang W, Liu X, et al
    Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cancer Lett. 2016 Oct 25. pii: S0304-3835(16)30646.
    PubMed     Text format     Abstract available


  7. GOWDA R, Sharma A, Robertson GP
    Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth.
    Cancer Lett. 2016 Oct 18. pii: S0304-3835(16)30628.
    PubMed     Text format     Abstract available


    September 2016
  8. LEE DG, Choi BK, Kim YH, Oh HS, et al
    The repopulating cancer cells in melanoma are characterized by increased mitochondrial membrane potential.
    Cancer Lett. 2016 Sep 5. pii: S0304-3835(16)30512.
    PubMed     Text format     Abstract available


    July 2016
  9. XU S, Wang H, Pan H, Shi Y, et al
    ANRIL lncRNA triggers efficient therapeutic efficacy by reprogramming the aberrant INK4-hub in melanoma.
    Cancer Lett. 2016 Jul 25. pii: S0304-3835(16)30441.
    PubMed     Text format     Abstract available


    May 2016
  10. LU Y, Wang Y, Miao L, Haynes M, et al
    Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.
    Cancer Lett. 2016 May 25. pii: S0304-3835(16)30338.
    PubMed     Text format     Abstract available


  11. BETTI M, Aspesi A, Biasi A, Casalone E, et al
    CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.
    Cancer Lett. 2016 May 12. pii: S0304-3835(16)30306.
    PubMed     Text format     Abstract available


    April 2016
  12. MATSUO K, Itoh T, Koyama A, Imamura R, et al
    CCR4 is critically involved in effective antitumor immunity in mice bearing intradermal B16 melanoma.
    Cancer Lett. 2016 Apr 28. pii: S0304-3835(16)30275.
    PubMed     Text format     Abstract available


  13. DASHTI A, Ebrahimi M, Hadjati J, Memarnejadian A, et al
    Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses.
    Cancer Lett. 2016;374:175-85.
    PubMed     Text format     Abstract available


  14. XIAO D, Barry S, Kmetz D, Egger M, et al
    Melanoma cell-derived exosomes promote epithelial-mesenchymal transition in primary melanocytes through paracrine/autocrine signaling in the tumor microenvironment.
    Cancer Lett. 2016 Apr 7. pii: S0304-3835(16)30211.
    PubMed     Text format     Abstract available


  15. JORDAN M, Waxman DJ
    CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
    Cancer Lett. 2016;373:88-96.
    PubMed     Text format     Abstract available


    March 2016
  16. DENG L, Fan J, Guo M, Huang B, et al
    Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
    Cancer Lett. 2016;372:251-7.
    PubMed     Text format     Abstract available


  17. ZHU G, Yi X, Haferkamp S, Hesbacher S, et al
    Combination with gamma-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.
    Cancer Lett. 2016 Mar 18. pii: S0304-3835(16)30178.
    PubMed     Text format     Abstract available


    January 2016
  18. TANG R, Xu X, Yang W, Yu W, et al
    MED27 promotes melanoma growth by targeting AKT/MAPK and NF-kappaB/iNOS signaling pathways.
    Cancer Lett. 2016 Jan 18. pii: S0304-3835(16)00017.
    PubMed     Text format     Abstract available


    December 2015
  19. CHEUNG M, Kadariya Y, Talarchek J, Pei J, et al
    Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction.
    Cancer Lett. 2015;369:261-5.
    PubMed     Text format     Abstract available


  20. COSTANTINO VV, Lobos-Gonzalez L, Ibanez J, Fernandez D, et al
    Dehydroleucodine inhibits tumor growth in a preclinical melanoma model by inducing cell cycle arrest, senescence and apoptosis.
    Cancer Lett. 2015 Dec 21. pii: S0304-3835(15)00740.
    PubMed     Text format     Abstract available


  21. DE AGUIAR RB, Parise CB, Souza CR, Braggion C, et al
    Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings.
    Cancer Lett. 2015 Dec 3. pii: S0304-3835(15)00720.
    PubMed     Text format     Abstract available


    November 2015
  22. LI Z, Jiang K, Zhu X, Lin G, et al
    Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells.
    Cancer Lett. 2015 Nov 14. pii: S0304-3835(15)00689.
    PubMed     Text format     Abstract available


    August 2015
  23. NOGUCHI S, Mori T, Igase M, Mizuno T, et al
    A novel apoptosis-inducing mechanism of 5-aza-2'-deoxycitidine in melanoma cells: demethylation of TNF-alpha and activation of FOXO1.
    Cancer Lett. 2015 Aug 31. pii: S0304-3835(15)00563.
    PubMed     Text format     Abstract available


  24. WANG Z, Cheng Q, Tang K, Sun Y, et al
    Lipid mediator lipoxin A4 inhibits tumor growth by targeting IL-10-producing regulatory B (Breg) cells.
    Cancer Lett. 2015;364:118-24.
    PubMed     Text format     Abstract available


    June 2015
  25. BETTUM IJ, Gorad SS, Barkovskaya A, Pettersen S, et al
    Metabolic reprogramming supports the invasive phenotype in malignant melanoma.
    Cancer Lett. 2015 Jun 18. pii: S0304-3835(15)00398.
    PubMed     Text format     Abstract available


  26. YANG X, Du T, Wang X, Zhang Y, et al
    IDH1, a CHOP and C/EBPbeta-responsive gene under ER stress, sensitizes human melanoma cells to hypoxia-induced apoptosis.
    Cancer Lett. 2015 Jun 3. pii: S0304-3835(15)00377.
    PubMed     Text format     Abstract available


    March 2015
  27. BERNARDES SS, de Souza-Neto FP, Ramalho LN, Derossi DR, et al
    Systemic oxidative profile after tumor removal and the tumor microenvironment in melanoma patients.
    Cancer Lett. 2015 Mar 12. pii: S0304-3835(15)00187.
    PubMed     Text format     Abstract available


    February 2015
  28. ZUBRILOV I, Sagi-Assif O, Izraely S, Meshel T, et al
    Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells.
    Cancer Lett. 2015 Feb 25. pii: S0304-3835(15)00155.
    PubMed     Text format     Abstract available


  29. ZHAO XP, Wang M, Song Y, Song K, et al
    Membrane microvesicles as mediators for melanoma-fibroblasts communication: roles of the VCAM-1/VLA-4 axis and the ERK1/2 signal pathway.
    Cancer Lett. 2015 Feb 4. pii: S0304-3835(15)00066.
    PubMed     Text format     Abstract available


    January 2015
  30. ALUPEI MC, Licarete E, Patras L, Banciu M, et al
    Liposomal simvastatin inhibits tumor growth via targeting tumor-associated macrophages-mediated oxidative stress.
    Cancer Lett. 2015;356.
    PubMed     Text format     Abstract available


  31. XIAO L, Yang S, Hao J, Yuan X, et al
    Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis.
    Cancer Lett. 2015 Jan 15. pii: S0304-3835(15)00034.
    PubMed     Text format     Abstract available


  32. STRICKLAND LR, Pal HC, Elmets CA, Afaq F, et al
    Targeting drivers of melanoma with synthetic small molecules and phytochemicals.
    Cancer Lett. 2015 Jan 15. pii: S0304-3835(15)00038.
    PubMed     Text format     Abstract available


  33. HAO M, Song F, Du X, Wang G, et al
    Advances in targeted therapy for unresectable melanoma: new drugs and combinations.
    Cancer Lett. 2015 Jan 8. pii: S0304-3835(15)00003.
    PubMed     Text format     Abstract available


    December 2014
  34. CHEN TC, Cho H, Wang W, Nguyen J, et al
    A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo.
    Cancer Lett. 2014 Dec 15. pii: S0304-3835(14)00764.
    PubMed     Text format     Abstract available


    November 2014
  35. CAPUTO E, Wang E, Valentino A, Crispi S, et al
    Ran signaling in melanoma: Implications for the development of alternative therapeutic strategies.
    Cancer Lett. 2014 Nov 20. pii: S0304-3835(14)00690.
    PubMed     Text format     Abstract available


  36. EL-KHATTOUTI A, Sheehan NT, Monico J, Drummond HA, et al
    CD133 melanoma subpopulation acquired resistance to caffeic acid phenethyl ester-induced apoptosis is attributed to the elevated expression of ABCB5: Significance for melanoma treatment.
    Cancer Lett. 2014 Nov 18. pii: S0304-3835(14)00654.
    PubMed     Text format     Abstract available


    October 2014
  37. GEORGAKILAS AG, Redon CE, Ferguson NF, Kryston TB, et al
    Systemic DNA damage accumulation under in vivo tumor growth can be inhibited by the antioxidant Tempol.
    Cancer Lett. 2014;353:248-57.
    PubMed     Text format     Abstract available


  38. AZZARITO T, Venturi G, Cesolini A, Fais S, et al
    Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma.
    Cancer Lett. 2014 Oct 23. pii: S0304-3835(14)00616.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: